FEBELFARMA
ActiveSummary
FEBELFARMA has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.0m and a net result of €45,753. Equity is growing by about 5% per year across the filed financial years. Its solvency ranks better than 95% of 3,840 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Directors
Board 4
Day-to-day management 2
Permanent representatives 3
Statutory auditor 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| ALEXO |
|
| ARISTO BV |
|
| Van Nueten Eric |
|
| BV KST Pharma |
|
| Moore Audit |
|
Owners and capital
Owners
1 ownerChain of control
- PHARMACIE BIA
- FEBELCO
- FEBELFARMA
Highest known parent: PHARMACIE BIA. The sources do not say who stands above it.
Owners 1
- FEBELCOparentSourceaccounts FEBELCO 202599.8%
According to the 2025 annual accounts of FEBELFARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.